DUBLIN – Domain Therapeutics SA could receive up to €240 million (US$257 million) in an up-front payment, potential milestones and eventual sales royalties from a licensing deal with Merck KgaA on its preclinical program of adenosine receptor modulators in development for immuno-oncology applications.